AU2023249891A1 - Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab - Google Patents

Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab Download PDF

Info

Publication number
AU2023249891A1
AU2023249891A1 AU2023249891A AU2023249891A AU2023249891A1 AU 2023249891 A1 AU2023249891 A1 AU 2023249891A1 AU 2023249891 A AU2023249891 A AU 2023249891A AU 2023249891 A AU2023249891 A AU 2023249891A AU 2023249891 A1 AU2023249891 A1 AU 2023249891A1
Authority
AU
Australia
Prior art keywords
antibody
subject
ivig
crovalimab
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023249891A
Other languages
English (en)
Other versions
AU2023249891A9 (en
Inventor
Simon Bertrand Marie BUATOIS
Keisuke GOTANDA
Kenji SHINOMIYA
Alexandre Antoine Bernard SOSTELLY
Antoine Paul Maxence SOUBRET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Original Assignee
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Chugai Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of AU2023249891A1 publication Critical patent/AU2023249891A1/en
Publication of AU2023249891A9 publication Critical patent/AU2023249891A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023249891A 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab Pending AU2023249891A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166585.4 2022-04-04
EP22166585 2022-04-04
PCT/EP2023/058608 WO2023194273A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (2)

Publication Number Publication Date
AU2023249891A1 true AU2023249891A1 (en) 2024-08-08
AU2023249891A9 AU2023249891A9 (en) 2024-08-15

Family

ID=81327202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023249891A Pending AU2023249891A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Country Status (11)

Country Link
US (1) US20250236662A1 (https=)
EP (1) EP4504774A1 (https=)
JP (1) JP2025511382A (https=)
KR (1) KR20240168984A (https=)
CN (1) CN118974082A (https=)
AU (1) AU2023249891A1 (https=)
CA (1) CA3251880A1 (https=)
IL (1) IL314751A (https=)
MX (1) MX2024012073A (https=)
TW (1) TW202404632A (https=)
WO (1) WO2023194273A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CR20220040A (es) * 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Also Published As

Publication number Publication date
MX2024012073A (es) 2024-11-08
CN118974082A (zh) 2024-11-15
WO2023194273A1 (en) 2023-10-12
US20250236662A1 (en) 2025-07-24
EP4504774A1 (en) 2025-02-12
CA3251880A1 (en) 2023-10-12
AU2023249891A9 (en) 2024-08-15
JP2025511382A (ja) 2025-04-15
TW202404632A (zh) 2024-02-01
KR20240168984A (ko) 2024-12-02
IL314751A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
KR20220044563A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
KR20250107839A (ko) 심혈관계 질환의 치료 방법
EP4055047A1 (en) Treatment for sjögren's syndrome
US20250236662A1 (en) Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab
US20250236661A1 (en) Dosage and administration regimen for the treatment or prevention of guillan-barre syndrome by the use of the anti-05 antibody crovalimab
US20230203149A1 (en) Treatment of atopic dermatitis
TW202337913A (zh) 每週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
KR20240014601A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
WO2025096435A1 (en) Treatment of complement-associated renal diseases
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
TW202345897A (zh) 每月投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
TW202345896A (zh) 每兩週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
CN119546641A (zh) 用baff或baff受体抑制性抗体的aiha的治疗
KR20250000093A (ko) Fviii 모방 이중특이적 항체의 격월 1회 투여 방법
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
AU2021296436A1 (en) Methods of treating Thyroid Eye Disease and Graves' Orbitopahy using Interleukin-17 (IL-17) antagonists

Legal Events

Date Code Title Description
SREP Specification republished